Private Wealth Management Group’s PharmaCyte Biotech PMCB Stock Holding History

Private Wealth Management Group’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-42	Closed	-$100	–	1590
2024 Q1	$100	Hold	42	–	–	﹤0.01%	1490
2023 Q4	$91	Buy	+42	New	+$91	﹤0.01%	1506

Other funds holding PMCB

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EPM

Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Private Wealth Management Group's PMCB Position: Q2 2024 in Review

Private Wealth Management Group sold out of PharmaCyte Biotech (PMCB) in Q2 2024, closing a stake of 42 shares — an estimated $100 sold.

Private Wealth Management Group first reported a position in PMCB in Q4 2023 and held it in 2 quarters. The position peaked at $100 in Q1 2024. 28 funds tracked by Wall St. Rank hold PMCB as of Q2 2024.

Private Wealth Management Group reported no remaining PharmaCyte Biotech position as of Q2 2024 after selling out during the quarter.
Private Wealth Management Group sold 42 PharmaCyte Biotech shares in Q2 2024, an estimated $100.
Private Wealth Management Group first reported a position in PharmaCyte Biotech in Q4 2023 and held it in 2 quarters.
Private Wealth Management Group's PharmaCyte Biotech position peaked at $100 in Q1 2024.
28 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2024.

Based on Private Wealth Management Group's 13F filing for Q2 2024, filed 13 Aug 2024.